Multi-Site Gram-negative Surveillance Initiative (MUGSI)
Multi-Site Gram-negative Surveillance Initiative (MUGSI)
Purpose
Gram-negative bacilli commonly cause infections in both health care and community settings. Emergence of resistance of these organisms to several antibiotics, such as carbapenems, makes treatment of these organisms more challenging. Examples of gram-negative bacilli include E. coli and K. pneumoniae. To monitor trends in the incidence of carbapenem resistant Enterobacteriaceae (“CRE”) and Extended-Spectrum β-Lactamases (ESBLs) Enterobacteriaceae, we conduct population-based surveillance among residents of Monroe County, NY, as part of the Centers for Disease Control and Prevention (CDC) Emerging Infections Program MUGSI initiative.
Goals and Objectives
- Determine the extent of CRE, carbapenem-resistant Acinetobacter and ESBLs disease in Monroe County
- Identify people most at risk for illness from these organisms
- Measure trends of disease over time
- Describe the epidemiology of bloodstream and urinary tract infections caused by E.coli to identify priority areas for future surveillance, public health interventions and vaccine development
Activities
Working with laboratories in Monroe County, the surveillance team identifies carbapenem resistant organisms, as well as those resistant to third generation cephalosporins. Demographic data and potential risk factors for infection and prior exposure to health care are collected. Selected isolates are sent to the CDC for further study.
Our Newsletter
Extended-Spectrum Beta-Lactamase Enterobacterales Surveillance, Monroe County, NY, 2020-2022
Publications
- Grome HN; Grass JE; Duffy N; Bulens SN; Ansari U; Campbell D; Lutgring JD; Gargis AS; Masters T; Kent AG; McKay SL; Smith G; Wilson LE; Vaeth E; Evenson B; Dumyati G; Tsay R; Phipps E; Flores K; Wilson CD; Czaja CA; Johnston H; Janelle SJ; Lynfield R; O'Malley S; Vagnone PS; Maloney M; Nadle J; Guh AY "Carbapenem-Resistant and Extended-Spectrum Beta-Lactamase-Producing Enterobacterales in Children, United States, 2016-2020." Emerging infectious diseases.. 2024; 30(6):1104-1114.
- Bulens, SN., Campbell, D., McKay, SL., Vlachos, N., Burgin, A., Burroughs, M. Padila, J., Grass, JE., Jacob, JT., Smith, G., Muleta, DB., Maloney, M., Macierowski, B., Wilson, LE., Vaeth, E., Lynfield, R., O’Malley, S., Snippes Vagnone, PM., Dale, J., Janelle, SJ., Czaja, CA., Johnson, H., Phipps, EC., Flores, KG., Dumyati, G., Tsay, R., et al., Carbapenem-resistant Acinetobacter baumannii complex in the United States – an epidemiological and molecular description of isolates collected through the Emerging Infections Program, 2019, American Journal of Infection Control, 2024,,ISSN 0196-6553, https://doi.org/10.1016/j.ajic.2024.04.184.
- Duffy, N., Li, R., Czaja, CA, Johnston, H., Janelle, SJ, Jacob JT, Smith G., Wilson LE, Vaeth E., Lynfield R., O’Malley S., Vagnone, PS, Dumyati G., Tsay R., Bulens SN, Grass JE, Pierce R., Cassidy, PM, Hertzel H., Wilson C., Muleta D., Taylor J., Guh AY, Trends in Incidence of Carbapenem-Resistant Enterobacterales (CRE) in Seven U.S. Sites, 2016─2020, Open Forum Infectious Diseases, 2023;, ofad609, https://doi.org/10.1093/ofid/ofad609
- Bulens, S., Reses, H., Uzma, A.,,Grass, J., Carmon, C., Albrecht, V., Dumyati, G.,Tsay, R., et al.(2022),Carbapenem-Resistant enterobacterales in individuals with and without health care risk factors —Emerging infections program, United States, 2012-2015, American Journal of Infection Control, ISSN 0196-6553, https://doi.org/10.1016/j.ajic.2022.04.003
- Duffy, N., Karlsson, M., Reses, H., Campbell, D., Daniels, J., Stanton, R., Tsay, R., Dumyati, G., et al. (2022). Epidemiology of extended-spectrum β-lactamase–producing Enterobacterales in five US sites participating in the Emerging Infections Program, 2017. Infection Control & Hospital Epidemiology, 1-9. doi:10.1017/ice.2021.496
- Wozniak JE; Band VI; Conley A; Rishishwar L; Burd EM; Satola SW; Hardy D; Tsay R; Farley MM; Jacob JT; Dumyati G; Jordan IK; Weiss DS. A Nationwide Screen of carbapenem-resistant reveals an isolate with enhanced virulence and clinically undetected colistin-heteroresistance. Antimicrob agents and chemother. 2019;Epub 2019 Feb 25. doi: 10.1128/AAC.00107-19.
- Bulens SN, Yi SH, Walters MS, Jacob JT, Bower C, Reno J, Wilson L, Vaeth E, Bamberg W, Janelle SJ, Lynfield R, Vagnone PS, Shaw K, Kainer M, Muleta D, Mounsey J, Dumyati G, Concannon C, Beldavs Z, Cassidy PM, Phipps EC, Kenslow N, Hancock EB, Kallen AJ. Carbapenem-Nonsusceptible Acinetobacter baumannii, 8 US Metropolitan Areas, 2012-2015External. Emerging Infectious Diseases. 2018 Apr;24(4):727-34. doi: 10.3201/eid2404.171461.
- Guh, A: Bulens., SN; Mu, Y; Jacob, JT; Reno, J; Scott, J; Wilson, LE, Sc,M; Vaeth, E; Lynfield, R; Shaw, KM; Snippes, PM; Vagnone, MT(ASCP); Bamberg, WM; Janelle, SJ; Dumyati, G; Concannon, C; Beldavs, Z; Cunningham, M; Cassidy, M; Phipps, EC; Kenslow, N; Travis, T; Lonsway, D; Rasheed, JK; Limbago, BM; Kallen, AJ. Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013. Journal of the American Medical Association. 5 October 2015.
- Magill, SS; Dumyati, G; Ray, SM; Fridkin, SK. Evaluating Epidemiology and Improving Surveillance of Infections Associated with Health Care, United States. Emerging infectious diseases. 2015 Sep; 21(9):1537-42.
- Chea N, Bulens SN, Kongphet-Tran T, Lynfield R, Shaw KM, Vagnone PS, Kainer MA, Muleta DB, Wilson L, Vaeth E, Dumyati G, Concannon C, Phipps EC, Culbreath K, Janelle SJ, Bamberg WM, Guh AY, Limbago B, Kallen AJ. Improved Phenotype-Based Definition for Identifying Carbapenemase Producers among Carbapenem-Resistant Enterobacteriaceae. Emerging Infectious Diseases. 2015 Sep;21(9):1611-1615. doi: https://dx.doi.org/10.3201/eid2109.150198.